Triple Negative Breast Neoplasms  >>  Halaven (eribulin mesylate)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Halaven (eribulin mesylate) / Eisai
NCT01698281 / 2012-000134-19: Phase 2 Trial of AEZS-108 in Chemotherapy Refractory in Triple Negative Breast Cancer

Terminated
2
7
US, Europe
AEZS-108, Zoptarelin doxorubicin, SCCC, Standard single agent cytotoxic chemotherapy, Dexamethasone
AEterna Zentaris
Breast Cancer
08/14
10/14

Download Options